Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68%) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48%) or allogeneic (58%) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplantrelated toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.
The first attempts to perform bone marrow transplantation in multiple myeloma were made with marrow from identical twins. 1, 2 The Seattle group recently reported results of syngeneic transplants in 11 patients. 3 Two of these patients are still surviving 9 and 15 years later without disease progression. Twenty-five syngeneic transplants performed Correspondence: Prof G Gahrton, Departments of Hematology and Medicine, Huddinge Hospital, SE-141 86 Huddinge, Sweden Received 13 January 1999; accepted 6 May 1999 throughout Europe have been reported to the registry of the European Group for Blood and Marrow Transplantation (EBMT). A preliminary non-case-matched study of these transplants 4 suggested that syngeneic transplantation in multiple myeloma might result in a lower transplant-related mortality than allogeneic transplantation, with a lower relapse risk than autologous transplantation. Although the number of syngeneic transplants is small, it has been possible to carry out a case-matched analysis of twin transplants and autologous transplants and also of twin transplants and allogeneic transplants. The aim was in particular to compare transplant-related mortality and relapse risk.
Patients and methods
The syngeneic transplants comprised 25 patients, 12 males and 13 females (Table 1) . Median age was 49 years (37-60). Four patients were stage IA at diagnosis, six stage IIa, 11 stage IIIA, two stage IIIB, and in two the stage was not known. The subtype was IgG in 16, IgA in four, IgD in one, light-chain in three, and IgG + IgA in one. The median time from diagnosis to transplantation was 10 months (0-98).
Pretransplant treatment varied. Two patients had received no treatment before conditioning for transplantation, 15 patients were on first line treatment, four on second line and four on third or more lines of treatment.
At the time of transplantation, four patients were in complete remission, 14 in partial remission, five were nonresponsive, and two had progressive disease according to previously published criteria. 5 The conditioning regimen varied considerably: two patients received TBI + cyclophosphamide, six TBI + melphalan, four TBI + melphalan + other cytotoxic drugs, eight melphalan alone, two busulfan + cyclophosphamide, and three a combination of other drugs. The source of stem cells was bone marrow in 24 patients and peripheral blood stem cells in one. Four patients received a second transplant and one further patient a third due to lack of complete remission or progressive disease (n = 3) following the previous transplant. The median follow-up time (estimated according to Parmar and Machin 6 after transplantation at the time of analysis was 55 months (2-111). 
Case-matching of twin transplants and autotransplants
Matching was based upon previously identified prognostic factors for autotransplantation. In a multivariate analysis it has been shown that the number of treatment lines pretransplant and response to pretransplant treatment regimens were the most powerful prognostic factors. 7 The twin transplants were therefore matched for the number of lines of treatment pretransplant (0-1 vs у2) and response status at transplantation (complete remission vs partial remission vs no response/progressive disease). The third matching variable was the date of transplantation, ie the nearest possible. Five autotransplants were selected to match each twin transplant. Thus, a total of 125 autotransplants, selected from 1279 such transplants in the EBMT registry (so-called 'complete reports' on Med-B forms), were compared to the 25 twin transplants. The cross match showed a fairly good similarity in the distribution of patients between other subgroups (Table 2) .
Case-matching of twin transplants and allogeneic transplants
The most powerful prognostic factor in allogeneic transplants has repeatedly been shown to be the sex of the recipient. 5, 8 The second most important factor is the number of lines of treatment before transplantation 5, 8 (as has been found in autotransplantation (see above)). These two variables were used for matching, in addition to the date of the transplantation, ie the nearest possible.
Five allogeneic transplants were selected to match each twin transplant. Thus, a total of 125 allogeneic transplants, selected from 315 such transplants in the EBMT registry (so-called 'complete reports' on Med-B forms), were compared to the 25 twin transplants. The cross-match showed a fairly good similarity in the distribution of patients between other prognostic subgroups ( Table 2) .
Results

Twin transplants
Out of the 25 twins, three were in complete remission before the transplant and 14 of the remaining 22 (64%) entered complete remission after transplantation ( Table 1) . The patients that were in complete remission before the transplant remained so after. Thus, a total of 17 patients (68%) were in complete remission following transplantation, 16 of them after the first transplant and one (patient No. 12) after the third. Four patients in partial remission before transplantation remained thus after the transplant, one previous responder entered partial remission and two non-responders remained thus. One patient died before evaluation of response. Five of the patients later underwent retransplantation because of progression (n = 4) or insufficient response (n = 1). In one of them a third transplant was performed. At the time of follow-up eight patients had died, six of their original disease and two of transplantrelated toxicity. Four of the patients who underwent retransplantation died of progressive myeloma and the patient who received a third transplant because of progressive disease died of veno-occlusive disease. Only one of the patients who underwent retransplantation was alive in partial 743 Table 2 Characteristics of patients 
Twin transplantation vs autotransplantation
Out of the 125 patients who had received an autologous transplant, 20 were in complete remission before transplantation and of the remaining 105 patients, 40 (38%) entered a complete remission. Thus, altogether 60 (48%) patients were in complete remission after transplantation. The overall survival in twin transplants vs autotransplants is shown in Figure 1 . The median overall survival in the autologous transplant group was 44 months and not significantly different from the overall survival in the twin group which was 73 months. The median progression-free survival was 25 months in the matched autotransplant group which was significantly different from the 72 months in the twin group (Figure 2 ). The relapse risk of patients in complete remission in the autotransplant group was 78% at 48 months while it was 36% in the twin (Figure 3 ). This difference in relapse risk was statistically significant (P = 0.009). Relapse rate in twin transplantation (36% at 48 months) compared to allogeneic transplantation (40% at 48 months). There was no significant difference (P = 0.99).
Twin transplants vs allotransplants
Out of the 125 patients who had received an allogeneic transplant, 20 were in complete remission before transplantation, and of the remaining 105 patients, 52 (50%) entered complete remission. Thus, altogether 72 (58%) patients were in complete remission after transplantation, which was not significantly different from that in the twin transplant group. However, the median survival in allotransplants was only 16 months which was significantly poorer than the median survival in the twin transplant group of 73 months (Figure 4 ). At 5 years the survival curves still diverged, 30% surviving in the allotransplant group and 54% in the twin group. The median progression-free survival was 9 months in the allogeneic group as compared to 72 months in the twin group. This, too, was statistically significant. The probability of treatment-related mortality was more than 40% in the allotransplant group while only two twins died of transplant-related mortality. However, the relapse risk of patients in complete remission was similar in the two groups ( Figure 5) . Thus, the difference in survival ( Figure 4 ) and progression-free survival was mainly due to the higher transplant-related mortality after allogeneic transplantation.
Discussion
This registry-based study of twin transplants in multiple myeloma is somewhat more encouraging than the study previously presented by Bensinger et al. 3 This study comprised 11 patients with advanced multiple myeloma. Although two out of the 11 patients were alive at 9 and 15 years post transplant, nine had succumbed at the time of follow-up as compared to eight out of 25 in our study. In Bensinger's study two patients died of early transplantrelated mortality and seven of progressive or relapsed disease at a median time of 32 months (range 3.5-57) post transplant. This is in contrast to our study with 17 patients still alive, of whom 13 were in complete remission at 5-111 months (median 29 months) post transplant. The reason for the apparently better outcome of patients in the EBMT registry is not clear. One reason may be that the patients in Bensinger's study appeared to have somewhat more advanced disease. However, another reason could be that most of the patients in Bensinger's study received TBI + cyclophosphamide or busulfan + cyclophosphamide for conditioning. Only one patient received a conditioning regimen that contained melphalan, while in the present EBMT study 18 out of the 25 patients received melphalancontaining regimens. It appears that early relapse is an important cause of death in Bensinger's study. Although progressive or recurring myeloma is also the main cause of death in our study (six patients died of myeloma), it may occur at a later stage if melphalan is included in the conditioning regimen. In autologous transplantation including melphalan in the conditioning regimen has previously been shown to be an important favourable prognostic factor. 7 Our study demonstrates significantly better results with syngeneic transplantation than with allogeneic transplantation, due to the higher treatment-related mortality in allotransplantation. The relapse rate seems to be similar with allogeneic and syngeneic transplantation. However, since only 17 patients in complete remission could be evaluated for relapse in the syngeneic group, a difference due to a graft-versus-myeloma effect in allogeneic transplants would be difficult to detect. It is interesting to note that graft-versus-host disease was reported in five twins, four of them still in complete remission, 10, 29, 56 and 109 months post transplant. A graft-versus-host-like disease has previously been reported in syngeneic transplants [9] [10] [11] and a possible graft-versus-leukaemia effect cannot be excluded. The mechanism is not known but if present could explain similar relapse rate in syngeneic and allogeneic transplants.
The overall survival with autologous transplantation did not differ significantly from that of twin transplantation. However, there was a non-significant trend in favour of better survival with twin transplants. This finding appeared to be due to a significantly lower relapse rate in the twin transplant group. It is possible that some of the relapses after autotransplantation may be due to infused malignant cells. Gene marking of malignant cells in acute leukaemia has shown that infused cells may give rise to relapse following autologous transplantation. 12 Studies are in progress to investigate whether this is a possibility in myeloma 13 but conclusive gene marking data are still lacking. Another explanation for the difference in relapse rate could have been a difference in the conditioning regimens. However, this is less likely since 18 of the 25 (72%) twin transplant patients had received melphalan-containing regimens, which was not statistically different from the percentage of patients who received melphalan-containing regimens in the autologous group (78%). Melphalan is, as mentioned above, the only variable in the conditioning regimens that has so far proven independently favourable for prognosis. Finally, syngeneic transplants may be associated with a graft-versus-myeloma effect (see above) not present in the autologous setting.
Autologous transplantation has previously been shown to be superior to both chemotherapy 14 and allogeneic transplantation for treatment of multiple myeloma. 15 Syngeneic transplantation appears to be at least as good as autologous transplantation and should therefore be performed in patients with stage II and stage III disease whenever there is an identical twin donor available.
